CompletedNCT04779216
Romosozumab and bone density in women with anorexia
About this title
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
Read the official source — NCT04779216Medication studyAges 20–60United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 20 years to 60 years.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 20, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Karen Klahr Miller, MD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 20 Years to 60 Years
- Official registry ID
- NCT04779216
- Official title
Show the full official title
Effects of Romosozumab on Bone Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Karen Klahr Miller, MD.
Did this study involve medication?
Yes. The study involved medication, including Romosozumab Prefilled Syringe, Placebo and Zoledronic acid 5 mg.
Who was this study for?
Listed age limits: 20 years to 60 years.
